|

Targeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease

RECRUITINGN/ASponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Actively Recruiting
PhaseN/A
SponsorCliniques universitaires Saint-Luc- Université Catholique de Louvain
Started2025-09-01
Est. completion2027-09
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06506513

Summary

Muscle changes including myosteatosis are reported as highly prevalent in metabolic dysfunction-associated steatotic liver disease (MASLD). Recent studies highlighted a link between muscle fat content and liver disease severity. Conversely, MASLD histological remission though diet or metabolic surgeries is also linked to a decrease in muscle fat content. Therefore, skeletal muscle appears as a potential target to treat MASLD.

Eligibility

Age: 18 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

* confirmed MASLD at abdominal imaging
* confirmed excessive muscle lipid content at imaging
* stable weight

Exclusion Criteria:

* severe comorbidities including active malignancies, neuromuscular degenerative diseases
* contraindications to physical activity
* excessive alcohol consumption

Conditions2

Liver DiseaseMetabolic Dysfunction-Associated Steatotic Liver Disease

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.